This protocol covers the first-line management of patients with advanced or metastatic typical lung carcinoid, or those with slowly progressing pulmonary neuroendocrine tumor confirmed positive on somatostatin receptor imaging (SRI).
Patients in this population present with advanced or metastatic typical lung carcinoid, or a slowly progressing lung carcinoid that is SRI-positive. In asymptomatic patients with slowly radiologically progressing disease, the rate of progression and receptor imaging status guide the choice between active treatment and close monitoring.
Management in this setting centres on somatostatin analogues as the recommended first-line systemic option. Locoregional strategies, including surgery, may be incorporated alongside systemic therapy to address tumour burden and hormonal effects. The complete structured regimen—including eligibility criteria, sequencing, and all recommended options—is available in the full protocol.
DOI: 10.1016/j.annonc.2021.01.003
SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
Watchful follow-up may be considered in asymptomatic patients with slowly radiologically progressing LCs [V, C]
Multiple locoregional therapies including surgery, combined or not with SSAs, are recommended to decrease the tumour burden, to control hormonal secretions and to prevent local complications, as a first-line therapeutic approach in patients with advanced slowly progressing LC [V, B].
View source ↗